NCT00487903View on ClinicalTrials.gov

Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Coronary Artery DiseaseHealthy
Interventions
DRUG

PB127 for Injectable Suspension

0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.

Trial Locations (3)

27710

Duke University Medical Center, Durham

66209

Midwest Cardiology Associates, Overland Park

75226

Baylor Research Institute, Dallas

Sponsors

Lead Sponsor

Point Biomedical
All Listed Sponsors
lead

Point Biomedical

INDUSTRY